Chemotherapy and targeted therapy are directed against micro-metastases, which are likely more prevalent in human epidermal growth factor receptor (HER)2-positive and triple-negative tumours, given the higher rates of systemic recurrence in tumours of these subtypes [6,7]. This evidence concerns the gene ERBB2 and neoplasm.